PKM and cancer: In contrast to the highly homologous alternatively spliced variant PKM1, which is thought to be constitutively active, PKM2 activity in cancer cells is maintained at a low level by the action of various allosteric ligands or post-translational modifications (PTMs) (Chaneton and Gottlieb, 2012).